Vaxart to Host Virtual Stockholder Fireside Chat on Wednesday, August 20 to Discuss Reverse Stock Split Proposal
Vaxart (OTCQX: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, will host a virtual stockholder fireside chat on August 20, 2025, at 4:30 p.m. ET to discuss its reverse stock split proposal. Leading proxy advisory firms ISS and Glass Lewis have recommended stockholders support the proposal, which aims to regain Nasdaq compliance.
The company's management team will address stockholder questions during the event, with investors able to submit questions in advance. Stockholders of record as of July 29, 2025, can vote on the proposal until September 4, 2025.
[]Vaxart (OTCQX: VXRT), una società biotech in fase clinica che sviluppa vaccini ricombinanti orali in formato pillola, terrà un incontro virtuale con gli azionisti il 20 agosto 2025 alle 16:30 ET per discutere la proposta di raggruppamento azionario (reverse stock split). Le principali società di consulenza per il voto per procura, ISS e Glass Lewis, hanno raccomandato agli azionisti di sostenere la proposta, finalizzata a ristabilire la conformità con il Nasdaq.
Il management risponderà alle domande degli azionisti durante l'evento e gli investitori potranno inviare quesiti in anticipo. Gli azionisti registrati alla data del 29 luglio 2025 potranno votare la proposta fino al 4 settembre 2025.
Vaxart (OTCQX: VXRT), una biotecnológica en fase clínica que desarrolla vacunas recombinantes orales en pastilla, celebrará un encuentro virtual con accionistas el 20 de agosto de 2025 a las 4:30 p.m. ET para tratar su propuesta de consolidación inversa de acciones (reverse stock split). Las principales firmas de asesoramiento de voto, ISS y Glass Lewis, han recomendado a los accionistas apoyar la propuesta, que busca recuperar el cumplimiento con Nasdaq.
El equipo directivo responderá preguntas de los accionistas durante el evento y los inversores podrán enviar preguntas por adelantado. Los accionistas registrados a fecha de 29 de julio de 2025 podrán votar la propuesta hasta el 4 de septiembre de 2025.
Vaxart (OTCQX: VXRT)는 경구용 재조합 필름백신(알약형)을 개발 중인 임상 단계 바이오텍 회사로, 2025년 8월 20일 오후 4시 30분(동부시간)에 주주들을 대상으로 리버스 스톡 스플릿(reverse stock split) 제안에 대해 논의하는 화상 간담회를 개최합니다. 주요 의결권 자문사인 ISS와 Glass Lewis는 이 제안에 대해 주주들의 지지를 권고했으며, 이는 나스닥 규정 준수를 회복하려는 목적입니다.
경영진은 행사에서 주주들의 질문에 답변할 예정이며, 투자자들은 사전에 질문을 제출할 수 있습니다. 2025년 7월 29일 기준 명부에 등록된 주주는 2025년 9월 4일까지 해당 안건에 대해 투표할 수 있습니다.
Vaxart (OTCQX: VXRT), une société de biotechnologie en phase clinique développant des vaccins recombinants oraux sous forme de comprimé, tiendra une discussion virtuelle avec les actionnaires le 20 août 2025 à 16h30 (heure de l'Est) pour expliquer sa proposition de reverse stock split (regroupement d'actions). Les principaux cabinets de conseil en vote, ISS et Glass Lewis, ont recommandé aux actionnaires d'approuver la proposition, qui vise à rétablir la conformité avec le Nasdaq.
L'équipe de direction répondra aux questions des actionnaires pendant l'événement, et les investisseurs pourront soumettre des questions à l'avance. Les actionnaires enregistrés au 29 juillet 2025 pourront voter sur la proposition jusqu'au 4 septembre 2025.
Vaxart (OTCQX: VXRT), ein Biotech-Unternehmen in der klinischen Phase, das orale rekombinante Tabletten-Impfstoffe entwickelt, wird am 20. August 2025 um 16:30 Uhr ET eine virtuelle Aktionärs‑Fireside‑Chat veranstalten, um seinen Vorschlag für einen Reverse‑Split zu erörtern. Die führenden Stimmrechtsberater ISS und Glass Lewis haben den Aktionären empfohlen, den Vorschlag zu unterstützen, der die Wiederherstellung der Nasdaq‑Compliance zum Ziel hat.
Das Management wird während der Veranstaltung Fragen der Aktionäre beantworten; Anleger können Fragen im Voraus einreichen. Aktionäre, die am 29. Juli 2025 als Eigentümer verzeichnet sind, können bis zum 4. September 2025 über den Vorschlag abstimmen.
- None.
- Company has been delisted from Nasdaq and currently trades on OTCQX
- Reverse stock split indicates potential share price challenges
Insights
Vaxart's reverse split proposal aims to regain Nasdaq listing, signaling financial challenges despite receiving proxy advisor support.
Vaxart's announcement reveals significant corporate governance developments as the company seeks shareholder approval for a reverse stock split. Currently trading on the OTCQX market (not Nasdaq), this critical vote aims to help the company regain Nasdaq compliance - a clear indication Vaxart has fallen below Nasdaq's continued listing requirements.
The endorsements from ISS and Glass Lewis - respected independent proxy advisory firms whose recommendations carry substantial weight with institutional investors - suggest the proposal has merit from a governance perspective. These firms typically support reverse splits only when they see a legitimate strategic rationale rather than mere cosmetic share price manipulation.
A reverse split mathematically increases the per-share price by reducing the number of outstanding shares, but doesn't fundamentally change company value. However, for Vaxart, Nasdaq relisting offers significant benefits: improved liquidity, broader access to capital, increased analyst coverage, and enhanced institutional investor interest.
The management's decision to host a fireside chat rather than simply collecting proxy votes demonstrates recognition of retail investor concerns. Reverse splits often face skepticism as they're frequently associated with struggling companies and can attract short sellers post-implementation.
Vaxart's current OTCQX status significantly limits its access to capital at a time when, as a clinical-stage biotech without marketable products, continued funding is essential for advancing its oral vaccine platform through expensive clinical trials.
- ISS and Glass Lewis, leading independent proxy advisory firms, support reverse stock split proposal -
- Webcast to begin at 4:30 p.m. ET / 1:30 p.m. PT -
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the senior management team will participate in a virtual stockholder fireside chat on Wednesday, August 20, 2025 at 4:30 p.m. ET / 1:30 p.m. PT.
“Our leadership team is excited for this opportunity to connect with our stockholders directly. This fireside chat is a chance for us to answer many of the frequently asked questions from our stockholders, particularly around the rationale for a reverse stock split and the need to regain Nasdaq compliance,” said Steven Lo, Chief Executive Officer of Vaxart.
A live webcast of the fireside chat will be available on the Company’s website at www.vaxart.com or by clicking here.
Investors may submit written questions in advance of the conference call to ir@vaxart.com or through the webcast portal. A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.
Leading independent proxy advisory firms, Institutional Shareholder Services (“ISS”) and Glass Lewis, recommend that stockholders support the reverse stock split proposal.
Vaxart encourages all stockholders of record on July 29, 2025, who have not yet voted to do so by 11:59 p.m. Eastern Time on September 4, 2025.
If you have any questions or need assistance with voting, please contact Vaxart’s proxy solicitation firm:
Campaign Management, LLC
Toll-Free: 1-855-264-1527
Email: info@campaign-mgmt.com
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
| Vaxart Media and Investor Relations: |
| Matt Steinberg |
| FINN Partners |
| IR@vaxart.com |
| (646) 871-8481 |
This press release was published by a CLEAR® Verified individual.
FAQ
When is Vaxart (VXRT) hosting its stockholder fireside chat about the reverse stock split?
Why is Vaxart (VXRT) proposing a reverse stock split?
How can Vaxart (VXRT) stockholders participate in voting for the reverse stock split?
What does Vaxart (VXRT) do as a company?
How can investors access Vaxart's stockholder fireside chat?
